Advanced search
Publication Cover
Drug Delivery Volume 25, 2018 - Issue 1
Submit an article Journal homepage
1,504
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity

Jian XuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; View further author information
,
Yue DuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; View further author information
,
Wen-Juan LiuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ;Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated to Shandong University Shandong Academy of Medical Sciences, Jinan, China; View further author information
,
Liang LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; View further author information
,
Yi LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; View further author information
,
Xiao-Fei WangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; View further author information
,
Hong-Fei YiWest China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, ChinaView further author information
,
Chuan-Kun ShanInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; View further author information
,
Gui-Min XiaInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; View further author information
,
Xiu-Jun LiuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Correspondence[email protected]
View further author information
&
Yong-Su ZhenInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Correspondence[email protected]
View further author information
 show all
Pages 102-111 | Received 13 Oct 2017, Accepted 23 Nov 2017, Published online: 17 Dec 2017

References

  • Atkinson SJ, English JL, Holway N, Murphy G. (2004). Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK-1 in HT1080 fibrosarcoma cells. FEBS Lett 566:65–70.
  • Bui-Nguyen B, Ray-Coquard I, Chevreau C, et al. (2012). High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol 23:777–84.
  • Gordon EM, Sankhala KK, Chawla N, Chawla SP. (2016). Trabectedin for soft tissue sarcoma: current status and future perspectives. Adv Ther 33:1055–71.
  • Gronchi A, Casali PG. (2013). Adjuvant therapy for high-risk soft tissue sarcoma in the adult. Curr Treat Options Oncol 14:415–24.
  • Harati K, Emmelmann S, Behr B, et al. (2016). Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo. Oncol Lett 11:1955–61.
  • Hong S, Ngo DN, Kim MM. (2016). Inhibitory effect of aminoethyl-chitooligosaccharides on invasion of human fibrosarcoma cells. Environ Toxicol Pharmacol 45:309–14.
  • Isaacson KJ, Martin Jensen M, Subrahmanyam NB, Ghandehari H. (2017). Matrix-metalloproteinases as targets for controlled delivery in cancer: an analysis of upregulation and expression. J Control Release 259:62–75.
  • Jablonska-Trypuc A, Matejczyk M, Rosochacki S. (2016). Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem 31:177–83.
  • Jackson HW, Defamie V, Waterhouse P, Khokha R. (2017). TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer 17:38–53.
  • Karavasilis V, Seddon BM, Ashley S, et al. (2008). Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112:1585–91.
  • Maquoi E, Noel A, Frankenne F, et al. (1998). Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett 424:262–6.
  • Min L, Choy E, Pollock RE, et al. (2017). Autophagy as a potential target for sarcoma treatment. Biochim Biophys Acta 1868:40–50.
  • Moore CS, Crocker SJ. (2012). An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 180:12–16.
  • Nonaka T, Nishibashi K, Itoh Y, et al. (2005). Competitive disruption of the tumor-promoting function of membrane type 1 matrix metalloproteinase/matrix metalloproteinase-14 in vivo. Mol Cancer Ther 4:1157–66.
  • Patrikidou A, Domont J, Cioffi A, Le Cesne A. (2011). Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol 12:21–31.
  • Radaelli S, Stacchiotti S, Casali PG, Gronchi A. (2014). Emerging therapies for adult soft tissue sarcoma. Expert Rev Anticancer Ther 14:689–704.
  • Riggi N, Cironi L, Suva ML, Stamenkovic I. (2007). Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET. J Pathol 213:4–20.
  • Steeg PS. (2016). Targeting metastasis. Nat Rev Cancer 16:201–18.
  • Togawa D, Koshino T, Saito T, et al. (1999). Highly activated matrix metalloproteinase-2 secreted from clones of metastatic lung nodules of nude mice injected with human fibrosarcoma HT1080. Cancer Lett 146:25–33.
  • Xia Y, Wu S. (2015). Tissue inhibitor of metalloproteinase 2 inhibits activation of the β-catenin signaling in melanoma cells. Cell Cycle 14:1666–74.
  • Xu J, Du Y, Liu XJ, et al. (2017). Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. Pharmacol Res 126:66–76.
  • Xu J, Liu XJ, Li L, et al. (2015). An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. Oncotarget 6:26322–34.
  • Yasue T, Tadokoro R, Takahashi Y. (2010). P02. Migration of human fibrosarcoma cells toward the blood vessel when transplanted into chicken embryo. Differentiation 80:S17–S8.
  • Yu SM, Kim SJ. (2016). 5-Azacytidine regulates matrix metalloproteinase-9 expression, and the migration and invasion of human fibrosarcoma HT1080 cells via PI3-kinase and ERK1/2 pathways. Int J Oncol 49:1241–7.
  • Zheng YB, Gong JH, Liu XJ, et al. (2017). A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis. Mol Carcinog 56:1395–404.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.